2021
DOI: 10.1016/j.ccr.2021.214104
|View full text |Cite
|
Sign up to set email alerts
|

Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
58
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 93 publications
(58 citation statements)
references
References 255 publications
0
58
0
Order By: Relevance
“…One approach to treating cancer is chemotherapy; several metal‐based drugs such as cisplatin and carboplatin are very widely used as anticancer agents [52] . Regrettably, these drugs possess high general toxicity and severe side effects due to their lack of selective action, while being inactive against some cancer cells and cancer metastases [53,54] …”
Section: Rationale For Ferrocene‐steroid Conjugates As Anticancer Agentsmentioning
confidence: 99%
See 1 more Smart Citation
“…One approach to treating cancer is chemotherapy; several metal‐based drugs such as cisplatin and carboplatin are very widely used as anticancer agents [52] . Regrettably, these drugs possess high general toxicity and severe side effects due to their lack of selective action, while being inactive against some cancer cells and cancer metastases [53,54] …”
Section: Rationale For Ferrocene‐steroid Conjugates As Anticancer Agentsmentioning
confidence: 99%
“…[52] Regrettably, these drugs possess high general toxicity and severe side effects due to their lack of selective action, while being inactive against some cancer cells and cancer metastases. [53,54] Free radical processes are known to be implicated in the pathology of cancer; most cancer cells produce abnormally high amounts of reactive oxygen species. [55,56] As a consequence of such an aberrant redox metabolism, compounds acting as free radicals or being able to produce free radical metabolites could be envisaged to inhibit cancer cell growth, possibly in a selective manner.…”
Section: Rationale For Ferrocene-steroid Conjugates As Anticancer Agentsmentioning
confidence: 99%
“…This means that Pd(II) compounds are much more reactive in solution which could lead to a higher toxicity and a different biological behaviour. However, the adequate selection of ligands could be able to stabilize Pd(II) complexes affecting their reactivity and imparting substitution inertness (Jahromi et al, 2016;Lazarević et al, 2017;Cirri et al, 2021;Czarnomysy et al, 2021;Yousuf et al, 2021).…”
Section: Strategies For the Rational Design Of Antiparasitic Metal Complexesmentioning
confidence: 99%
“…However, the discovery of the potent anti-tumor activity of cisplatin, [PtCl 2 (NH 3 ) 2 ] determined the beginning of the modern era of Medicinal inorganic chemistry, accompanied by a huge impact of metal compounds in modern medicine. By exploiting the unique properties of metal ions, Medicinal inorganic chemistry currently offers an attractive option for the rational design of new drugs, looking for defined targets and activities, and new diagnostic and theranostic tools (Zhang and Sadler, 2017;Hanif and Hartinger, 2018;Englinger et al, 2019;Kostelnik and Orvig, 2019;Soldevila-Barreda and Metzler-Nolte, 2019;WahsnerGale et al, 2019;Wang et al, 2019;Anthony et al, 2020;Chamberlain et al, 2020;Chellan and Sadler, 2020;Imberti et al, 2020;Murray and Dyson, 2020;Cirri et al, 2021;Karges and Cohen, 2021;Lin et al, 2021;Silva et al, 2021;Yousuf et al, 2021). In the last decades, the development of metal-based drugs has proven to be a promising approach in the search for new therapeutic tools against parasitic diseases.…”
Section: Introductionmentioning
confidence: 99%
“…In this context, other metallic compounds with better biological and pharmacological properties are needed. Rutheniums have emerged as a novel and promising anticancer family of agents [10,11]. Ruthenium-based therapy might overcome platinum resistance, and improve the narrow therapeutic window of 'the platinum family of agents' [12,13].…”
Section: Introductionmentioning
confidence: 99%